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Abstract. 
 
We have recently cloned and characterized 
ankyrin-3 (also called ankyrin
 
G
 
), a new ankyrin that is 
widely distributed, especially in epithelial tissues, mus-
cle, and neuronal axons (Peters, L.L., K.M. John, F.M. 
Lu, E.M. Eicher, A. Higgins, M. Yialamas, L.C. Turtzo, 
A.J. Otsuka, and S.E. Lux. 1995. 
 
J. Cell Biol.
 
 130:
313–330). Here we show that in mouse macrophages, 
ankyrin-3 is expressed exclusively as two small isoforms 
(120 and 100 kD) that lack the NH
 
2
 
-terminal repeats. 
Sequence analysis of isolated Ank3 cDNA clones, ob-
tained by reverse transcription and amplification of 
mouse macrophage RNA (GenBank Nos. U89274 and 
U89275), reveals spectrin-binding and regulatory do-
mains identical to those in kidney ankyrin-3 (GenBank 
No. L40631) preceded by a 29–amino acid segment of 
the membrane (“repeat”) domain, beginning near the 
end of the last repeat. Antibodies specific for the regu-
latory and spectrin-binding domains of ankyrin-3 local-
ize the protein to the surface of intracellular vesicles 
throughout the macrophage cytoplasm. It is not found 
on the plasma membrane. Also, epitope-tagged mouse 
macrophage ankyrin-3, transiently expressed in COS 
cells, associates with intracellular, not plasma, mem-
branes. In contrast, ankyrin-1 (erythrocyte ankyrin, 
ankyrin
 
R
 
), which is also expressed in mouse macro-
phages, is located exclusively on the plasma membrane. 
The ankyrin-3–positive vesicles appear dark on phase-
contrast microscopy. Two observations suggest that 
they are lysosomes. First, they are a late compartment 
in the endocytic pathway. They are only accessible to a 
fluorescent endocytic tracer (FITC-dextran) after a 
24-h incubation, at which time all of the FITC-dextran–
containing vesicles contain ankyrin-3 and vice versa. 
Second, the ankyrin-3–positive vesicles contain lyso-
somal-associated membrane glycoprotein (LAMP-1), a 
recognized lysosomal marker. This is the first evidence 
for the association of an ankyrin with lysosomes and is 
an example of two ankyrins present in the same cell 
that segregate to different locations.
 
T
 
he
 
 ankyrins are a family of plasma membrane–asso-
ciated proteins that link integral membrane proteins
to the underlying membrane skeleton. There are now
three family members: erythrocyte ankyrin (ankyrin-1,
 
Ank1
 
, Ank
 
R
 
) (42, 48), brain ankyrin (ankyrin-2, 
 
Ank2
 
,
Ank
 
B
 
) (58), and epithelial or general ankyrin (ankyrin-3,
 
Ank3
 
, Ank
 
G
 
) (37, 60).
In the RBC, ankyrin-1 links the transmembrane anion
exchanger, band 3, to 
 
b
 
-spectrin and the plasma mem-
brane skeleton (3, 4, 13, 33). This linkage is critical for the
stability of the lipid bilayer (61). Defects in ankyrin-1 or its
attached proteins result in a spherocytic hemolytic anemia
(11, 21, 49, 75) due to excessive vesiculation of RBC mem-
brane lipids. Ankyrin-1 is also expressed in muscle (6), en-
dothelial cells (Lux, S.E., unpublished data), cerebellar
Purkinje cells and granule cells, and a subset of spinal cord
and hippocampal neurons (34, 59).
Ankyrin-2 is the major form of ankyrin in the nervous
system. The 220-kD protein is found in most neuron cell
bodies and dendrites, as well as in glia (58). A 440-kD iso-
form is expressed in the fetal brain, targeted specifically to
unmyelinated axons and dendrites (8, 40).
Ankyrin-3 is much more widely distributed than its sis-
ter genes and is the major ankyrin in epithelia, myocytes,
hepatocytes, melanocytes, megakaryocytes, Leydig cells,
and neuronal axons (60). In the brain, ankyrin-3 is ex-
pressed as isoforms of 270- and 480-kD and localizes to the
nodes of Ranvier and to the initial segments of axons (34,
37, 60).
All three ankyrins have a similar, three-domain struc-
ture. The NH
 
2
 
-terminal, plasma membrane–binding or
“repeat” domain contains 24 tandem 33–amino acid re-
peats and binds many of the integral membrane protein
ligands of ankyrins (12, 50–52). The central, spectrin-bind-
ing domain binds spectrin and fodrin (nonerythroid spec-
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trin) (2, 3, 14, 33, 62) and is critical for attaching the under-
lying membrane skeleton to the lipid bilayer. The COOH-
terminal, regulatory domain influences the affinity of ankyrin
for its ligands via an acidic, alternately spliced segment in
the middle of the domain (14).
The kidney contains multiple isoforms of ankyrin-3: 215,
200, 170, 120, and 105 kD (60). The two smallest isoforms
lack the repeat domain and differ only by the presence or
absence of the acidic regulatory domain insert (60). These
two small ankyrin-3 isoforms are the only forms observed
in intestine, testis, and liver. Immunohistochemical stain-
ing suggests they reside in the cytoplasm instead of in the
plasma membrane (60).
We find that two similar, small, NH
 
2
 
-terminal truncated
proteins are also the only isoforms of ankyrin-3 in bone
marrow–derived macrophages, where they associate with
intracellular membranes of phase-dense lysosomes (i.e.,
lysosomes that appear dense in the phase-contrast micro-
scope). Judging from when they are labeled by soluble,
fluid-phase tracer molecules (25, 68, 71), these vesicles oc-
cur very late in the endocytic pathway. Specifically, 24 h
after an initial 15-min pulse, fluorescence from endocy-
tically incorporated dextrans completely coincides with
staining from ankyrin-3 antibodies. Taken together with im-
munofluorescent experiments that show both ankyrin-3 and
lysosomal-associated membrane glycoprotein 1 (LAMP-1)
 
1
 
on the same late endocytic vesicles, we identify these vesi-
cles as lysosomes.
 
Materials and Methods
 
Macrophages
 
Murine bone marrow–derived macrophages were obtained as previously
described (70). Briefly, femurs from C3H-HeJ 
 
1
 
/
 
1
 
 mice (The Jackson
Laboratory, Bar Harbor, ME) were removed and their marrow was ex-
truded and cultured in bone marrow macrophage medium (BMM) for 6–7 d.
BMM comprises DME (GIBCO BRL, Gaithersburg, MD) containing
30% L cell–conditioned medium, a source of macrophage colony stimulat-
ing factor, and 20% heat-inactivated FBS (Biocell Laboratories, Rancho
Dominguez, CA). Cells were harvested and either plated onto glass cover-
slips and incubated overnight to allow cells to adhere for immunofluores-
cence or replated at one-third density and allowed to grow for an addi-
tional 2 d before harvesting protein or RNA.
 
Antibodies
 
Ankyrin-3 antibodies were generated and characterized previously in our
laboratory (60). Briefly, a unique portion of the regulatory domain of
mouse ankyrin-3 was fused to glutathione-
 
S
 
-transferase (GST) and used
as an antigen (Ank3-R1 antibody). Also, antibodies were prepared to the
“B” insert (DKCTWFKIPKVQEVL), which lies between the repeat and
spectrin-binding domains, and to the NH
 
2
 
-terminal end of the kidney iso-
form lacking the repeat domain (MALPHSEDAITGDTD). These are re-
ferred to as Ank3-B and 5
 
9
 
Ank3, respectively (60). Anti–human ankyrin-1
antibodies were prepared against a mixture of native and SDS-denatured
ankyrin as previously described (66). Anti–hemagglutinin (HA) mAb
(12CA5) was obtained from Boehringer Mannheim Biochemicals (India-
napolis, IN). Anti–LAMP-1 sera were obtained from the Developmental
Studies Hybridoma Bank maintained by the Department of Pharmacol-
ogy and Molecular Sciences (Johns Hopkins University School of Medi-
cine, Baltimore, MD), and from the Department of Biological Sciences
(University of Iowa, Iowa City, IA) (under contract N01-HD-6-2915 from
the National Institute of Child Health and Human Development). The
anti-rab9 antiserum was provided by Dr. Angela Wandinger-Ness (North-
western University, Evanston, IL). Anti–
 
a
 
-spectrin, anti-adducin, and anti–
protein 4.1 antibodies were provided by Dr. Shih-Chun Liu (St. Eliza-
beth’s Hospital, Brighton, MA) (17,46). The adducin antiserum was raised
against both 
 
a
 
- and 
 
b
 
-adducin. Anti–canine erythrocyte 
 
b
 
-spectrin and
ankyrin antibodies, provided by Dr. Kenneth Beck (Stanford University,
Stanford, CA) (1), detect Golgi spectrin and ankyrin, respectively, in
MDCK cells (1).
Anti–human erythrocyte protein 4.1 and eight different anti–human
spectrin antisera were provided by Dr. Orah Platt (Children’s Hospital,
Boston, MA). Affinity-purified antibodies against 
 
b
 
-actin were provided
by Dr. Ira Herman (Tufts University School of Medicine, Boston, MA)
(28). Anti–GP-260 antibodies, which were raised against an 
 
Acantha-
moeba
 
 protein immunologically related to 
 
b
 
-spectrin, were provided by
Dr. Tom Pollard (Johns Hopkins University School of Medicine, Balti-
more, MD) (63). Anti–human brain fodrin antibodies were provided by
Dr. Jon Morrow (Yale University School of Medicine, New Haven, CT)
(27). Anti–bovine brain fodrin antibodies were provided by Dr. Shin Lin
(Johns Hopkins University) (45). Affinity-purified anti–guinea pig brain
fodrin antibodies were provided by Dr. Mark Willard (Washington Uni-
versity School of Medicine, St. Louis, MO) (43). All of the fodrin antisera
were raised against both 
 
a
 
- and 
 
b
 
-fodrin.
 
Preparation of Proteins
 
Kidney membrane proteins were prepared as previously described (60).
Macrophage protein extracts were prepared by lysing dense but not con-
fluent macrophages from one well of a six-well dish into 1 ml of extraction
buffer (16) containing 0.5% SDS, 0.1% Triton X-100, 40 mM Hepes, pH
7.15, 50 mM Pipes, pH 6.9, 75 mM NaCl, 1 mM MgCl
 
2
 
, 0.5 mM EGTA, 0.1
mg/ml leupeptin, 0.1 mg/ml pepstatinA, and 0.1 mg/ml PMSF (first dis-
solved in 100% ethanol). Extracts were immediately added to one-third
volume of 4
 
3
 
 Laemmli sample buffer (41), boiled for 5 min, and applied
to SDS polyacrylamide gels.
 
Immunoblotting
 
SDS-PAGE was performed using the Laemmli buffer system (41) with
5% stacking and 10% running gels. 30 
 
m
 
l (50–100 
 
m
 
g) of macrophage ex-
tracts or kidney membrane proteins and 30 
 
m
 
l (
 
z
 
200 
 
m
 
g) of prestained
molecular weight markers (Bio Rad Laboratories, Hercules, CA) were run
overnight at a constant 30 V. The proteins were transferred to Immobil-
onP membranes (Millipore Corp., Bedford, MA) in 48 mM Tris-HCl, 39 mM
glycine, 20% methanol, and 0.0375% SDS, pH 8.3, using a BioRad semi-
dry transfer apparatus. Filters were blocked for a minimum of 1 h at room
temperature in TTBS (10 mM Tris HCl, pH 7.0, 0.05% Tween-20, and 150
mM NaCl) containing 5% BSA. Filters were washed three times for 5 min
each in TTBS, and then incubated for 1 h at room temperature in primary
antibody diluted 1:500 in TTBS. Washing was repeated as above, and then
filters were incubated at room temperature with goat anti–rabbit IgG con-
jugated with alkaline phosphatase (Bio Rad Laboratories) according to
the manufacturer’s instructions. Filters were washed again as above, and
bound antibody was visualized with nitroblue tetrazolium and 5-bromo-4-
chloro-3-indolyl phosphate (BioRad kit).
 
Preparation of RNA
 
Medium was removed from macrophage cultures by aspiration, and each
monolayer was washed twice with ice-cold PBS lacking calcium and mag-
nesium. For 150-mm dishes, 4.5 ml of 10 mM EDTA, pH 8.0, containing
0.5% SDS was added, and the lysate was scraped off the dish and collected
into a glass centrifuge tube. Then 4.5 ml of 0.1 M sodium acetate, pH 5.2,
containing 10 mM EDTA, pH 8.0, was used to rinse the plate; the eluate
was collected and added to the lysate. Water saturated phenol (9 ml) was
added to the lysate and the mixture was shaken vigorously at room tem-
perature for 2 min. Aqueous and organic phases were separated by a 10-
min centrifuge spin at 4
 
8
 
C at 3,000 g. The aqueous phase was reextracted
twice more, once in a 24:24:1 mixture of phenol/chloroform/isoamyl alco-
hol and once in a 24:1 mixture of chloroform/isoamyl alcohol. Ice-cold 1 M
Tris-HCl (pH 8.0, 990 
 
m
 
l) and 5 M NaCl (405 
 
m
 
l) were added to the aque-
ous phase and mixed. 2 vol of ice-cold ethanol were then added, and the
precipitated RNA was centrifuged for 15 min at 4
 
8
 
C at 12,000 
 
g
 
. The RNA
was redissolved and reprecipitated as above, and then dissolved in ice-
cold 10 mM Tris and 1 mM EDTA, pH 8.0.
 
1. 
 
Abbreviations used in this paper
 
: aa, amino acid; BMM, bone marrow
macrophage medium; GST, glutathione-
 
S
 
-transferase; HA, hemaggluti-
nin; IL, interleukin; LAMP-1, lysosomal-associated membrane glycopro-
tein 1; RACE, rapid amplification of cDNA ends; RT, reverse transcrip-
tion. 
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Reverse Transcription–PCR
 
Macrophage RNA (5 
 
m
 
g) was heated to 65
 
8
 
C for 5 min and transferred
to ice for an additional 5 min. Denatured RNA was then added to a buffer
containing 50 mM Tris-HCl, pH 8.3, 75 mM KCl, 3 mM MgCl
 
2
 
, 10 mM DTT,
0.5 mM each of dGTP, dATP, dCTP, and dTTP, 10–50 
 
m
 
g/ml oligo(dT), 1 
 
m
 
l
(40 U) of RNAsin (Promega, Madison, WI), and 4 
 
m
 
l (800 U) of Moloney
murine leukemia virus reverse transcriptase (GIBCO BRL) and incu-
bated at 42
 
8
 
C for 60 min. RNA was then hydrolyzed by adding NaOH to a
final concentration of 0.375 N at 65
 
8
 
C for 30 min. The base was neutral-
ized with an equal molar amount of acetic acid. cDNA was amplified using
AmpliTAQ (Boehringer Mannheim Biochemicals) with isoform-specific
ankyrin-3 primers (see Fig. 1) (15 ng/
 
m
 
l) in a buffer containing 100 mM
Tris-HCl, pH 8.3, 15 mM MgCl
 
2
 
, 500 mM KCl, and 0.2 mM dNTP. The
PCR program was 94
 
8
 
C (30 s), 60
 
8
 
C (30 s), and 72
 
8
 
C (5 min) for 30 cycles
followed by extension at 72
 
8
 
C (7 min).
Primer sequences were: REGR1; 5
 
9
 
-ACTGGCAGTATGACCAA-
GTGGTCCTGGACTGAC-3
 
9
 
 (Tm 
 
5
 
 70.7
 
8
 
C); REGF1; 5
 
9
 
-CACATA-
AAAAGGCTGAGAAGGCAGACAGACGCC-3
 
9
 
 (Tm 
 
5
 
 70.7
 
8
 
C); SPR1;
5
 
9
 
-GGACTCATGCTGGGTTCAGTCAAGTAGCTGTAG-3
 
9
 
 (Tm 
 
5
 
70.0
 
8
 
C); SPINTF1; 5
 
9
 
-GAAGATGCCATCACAGGGGACACTGAC-
AAG-3
 
9
 
 (Tm 
 
5
 
 69.5
 
8
 
C); SP7F1; 5
 
9
 
-ACAAAATGAATGTCCCAGAAA-
CGATGAATGAAG-3
 
9
 
 (Tm 
 
5
 
 63.3
 
8
 
C); SPEC5F1; 5
 
9
 
-GGACGGCTT-
ACTCTAAACCCCTGCTTAAGGAAT-3
 
9
 
 (Tm 
 
5
 
 69.4
 
8
 
C); MEMF1;
5
 
9
 
-GATCTCCTGCCTCGTCTCAACTCCCCTGATCTC-3
 
9
 
 (Tm 
 
5
 
 73.2
 
8
 
C).
 
5
 
9
 
-RACE PCR
 
Amplification of the 5
 
9
 
 end of macrophage ankyrin-3 was carried out as
described by the manufacturer using the 5
 
9
 
/3
 
9
 
 RACE kit (Boehringer
Mannheim Biochemicals). Briefly, RACE products were generated by
MEMR3 priming the reverse transcription, and MEMR1 and MEMR2
priming the primary and nested PCR reactions. Additional reactions used
the MEMR2 primer for the reverse transcription, and 5PRR1 and 5PRR2
(which are located at the extreme 3
 
9
 
 end of the repeat domain) for prim-
ing the primary and nested PCR reactions.
Primer sequences were: MEMR1; 5
 
9
 
-ACCTTCTGCTGGCAGGGA-
GTCATCACCTAGCTC-3
 
9
 
 (Tm 
 
5
 
 72.9
 
8
 
C); MEMR2; 5
 
9
 
-AAGGTCCTG-
TGGCCCGAGATACTTGTCAGTGTC-3
 
9
 
 (Tm 
 
5
 
 71.9
 
8
 
C); MEMR3;
5
 
9
 
-GTAGGACCTATCCGAACTGAAGGAGCGGAGGC-3
 
9
 
 (Tm 
 
5
 
71.3
 
8
 
C); 5PRR1; 5
 
9
 
-AGGCGTTGTTCTGAAGCAAGACATTGATGA-
TAT-3
 
9
 
 (Tm 
 
5
 
 65.7
 
8
 
C); 5PRR2; 5
 
9
 
-CCTGCTGAGCAGCCTGGTG-
CAGTGCTGTGTATC-3
 
9
 
 (Tm 
 
5
 
 74.4
 
8
 
C).
 
DNA Sequencing
 
PCR products were isolated and subcloned into the pCR II vector using
the TA cloning kit (Invitrogen, San Diego, CA). Plasmid DNA was pre-
pared by the cetyltrimethylammonium bromide method (15) and se-
quenced on both strands by the dideoxynucleotide chain termination
method (65) using Sequenase version 2.0 (United States Biochemical
Corp., Cleveland, OH) and synthetic oligonucleotide primers.
 
Immunofluorescence Microscopy
 
For ankyrin-3 localization, cells plated onto glass coverslips were fixed in
4% paraformaldehyde at room temperature for 5 min, and then lysed in a
0.1% Triton X-100 buffer containing 40 mM Hepes, pH 7.15, 50 mM
Pipes, pH 6.9, 75 mM NaCl, 1 mM MgCl
 
2
 
, and 0.5 mM EGTA as described
previously (16). For LAMP-1 localization, cells plated onto glass cover-
slips were fixed in 50 mM phosphate buffer, pH 7.8, containing 2% para-
formaldehyde, 9 mg/ml lysine, and 2 mg/ml NaIO
 
4
 
 for 1–2 h. The fixed
cells were permeabilized in 0.01% saponin.
For double immunofluorescence experiments, cells were fixed as de-
scribed for LAMP-1 but were lysed in 0.25% saponin. Both LAMP-1 and
ankyrin-3 were detectable under these conditions, although staining of
each protein was less intense than it was under the optimal conditions of
cell lysis described above (LAMP-1 
 
5
 
 0.01% saponin; ankyrin-3 
 
5
 
 0.1%
Triton X-100). This was particularly true for ankyrin-3, which was barely
detectable in cells lysed with saponin. In a survey experiment, 0.25% sa-
ponin was the only concentration where both ankyrin-3 and LAMP-1
could be detected. The number of LAMP-1–positive or dextran-filled ves-
icles observed was reduced when higher concentrations of saponin were
used for lysis or completely ablated when Triton X-100 was used instead
of saponin.
All cells were then washed three times (5 min each) in 2 ml of PBS con-
taining 0.02% NaN
 
3
 
 at room temperature, and then incubated at room
temperature for 1 h with primary antibodies diluted in PBS. Cells were
washed in PBS again and incubated for 1 h at room temperature with a 1:800
dilution of a goat anti–rabbit or goat anti–mouse secondary antibody con-
jugated with the fluorochrome CY-3 (Jackson ImmunoResearch Labora-
tories, West Grove, PA). Stained cells were washed a final time, mounted
in 9:1 glycerol/PBS, and visualized on an Axiochrom microscope (Carl
Zeiss Inc., Thornwood, NY). Images were captured on T-Max 400 film
(Eastman Kodak Co., Rochester, NY).
 
Labeling of Endocytic Organelles
 
Dextran was used as an endocytic tracer. Macrophages were incubated at
37
 
8
 
C for 15 min in BMM containing 10 mg/ml of an anionic, fluorescein-
conjugated dextran (
 
M
 
r
 
 10,000) that could be fixed with paraformalde-
hyde (Molecular Probes, Eugene, OR). The cells were then washed and
chased with BMM (not containing dextran) for periods up to 24 h. The
dextran-treated cells were processed at specific time points for immuno-
fluorescence microscopy as described above.
 
Expression of Epitope-tagged Ankyrin-3 in COS Cells
 
The HA epitope was fused to the COOH terminus of mouse macrophage
ankyrin-3 and ligated into the pcDNA3 vector (Invitrogen). The vector
used in transfection experiments was purified by alkaline lysis and cesium
chloride density gradient centrifugation as described previously (64). Puri-
fied vector was transfected into COS cells using the ProFection CaPO4
transfection kit (Promega, Madison, WI) according to manufacturer’s rec-
ommendations. Cells were allowed to take up the DNA for 16 h, washed,
and incubated for an additional 2 d before HA-tagged ankyrin-3 was visu-
alized via immunofluorescence using the monoclonal 12CA5 anti-HA an-
tibody (Boehringer Mannheim Biochemicals) as described above.
Results
Macrophage Ankyrin-3 Lacks the
NH2-terminal Repeats
In the mouse kidney, ankyrin-3 is expressed as multiple
isoforms (see Fig. 2) that are detected by Western blotting
with the Ank3-R1 antibody (60) (Fig. 1). Antibody stain-
ing is specific since it is successfully competed by the im-
Figure 1. Schematic diagram of ankyrin-3 protein isoforms and
location of antibody epitopes and PCR primers. Ank3-B is a pep-
tide antibody against the B insert, 59Ank3 is a peptide antibody
directed against the NH2-terminal region of the spectrin-binding
domain and the short 59 exon from the 120- and 105-kD isoforms
present in kidney, and Ank3-R1 is a polyclonal antibody against
the regulatory domain. The positions of the antigens used for
those antibodies are displayed as well as the positions of the for-
ward and reverse primers used in RT-PCR experiments.The Journal of Cell Biology, Volume 136, 1997 1062
munizing antigen (Fig. 2, lane C). The calculated molecu-
lar masses, based on mobility in SDS polyacrylamide gels,
are 215, 200, 170, 120, and 105 kD (60). We have previ-
ously shown that the two smallest isoforms (105 and 120 kD)
lack the NH2-terminal repeat domain (60). Bone marrow–
derived macrophages also express small (120 and 100 kD)
isoforms of ankyrin-3 (Fig. 2, lane D, arrows). These iso-
forms are specific (Fig. 2, lane E) and are the only forms of
ankyrin-3 consistently observed in macrophages. Some
gels contain other, lower molecular mass bands (,80 kD)
that stain specifically with Ank3-R1 (Fig. 2, lanes D and
E), but these are probably proteolytic fragments of the
larger bands because they vary in size and intensity from ex-
periment to experiment.
To further characterize the macrophage forms of ankyrin-3
and the analogous kidney isoforms, we recloned ankyrin-3
from mouse bone marrow–derived macrophage RNA by
reverse transcription (RT)–PCR. Primers that flank the reg-
ulatory domain (REGF1 and REGR1; Fig. 1) produce two
PCR products of z1,025 and 1,600 bp (Fig. 3, lane A, ar-
rows). Subcloning (Fig. 3, lanes G and H) and sequencing
show these represent the regulatory domain with and
without the acidic, alternatively spliced exon that is lo-
cated in the center of the domain (for review see Fig. 1).
The spectrin-binding domain is also present in macrophage
RNA as shown by the 1,800-bp product (Fig. 3, lane C, ar-
row) obtained using primers SPINTF1 and SPR1 (Fig. 1).
The identity of this domain was also confirmed by subclon-
ing (Fig. 3, lane F) and sequencing. Interestingly, primers
MEMF1 and MEMR1 (Fig. 1) did not yield a product.
This result supports the protein analysis and confirms that
the NH2-terminal repeats of ankyrin-3 are not present in
macrophage RNA. All macrophage ankyrin-3 cDNAs
were completely sequenced and compared with ankyrin-3
cDNA clones from kidney. This analysis revealed that
macrophage ankyrin-3 contains all of the sequence of the
spectrin-binding (amino acids [aa] 874–1,455) and regula-
tory (aa 1,456–1,960) domains previously reported from
mouse kidney (60) (GenBank No. L40631). The two iso-
forms of ankyrin-3 expressed in macrophages differ from
each other only by the presence or absence of an insert in
the regulatory domain (aa 1,588–1,783) that is also found
in kidney ankyrin-3 (60) and is analogous in size and
charge to the “2.1 insert” in the regulatory domain of
ankyrin-1 (42, 48).
It is important to note that the primer SP5F1, which hy-
bridizes to the 59 untranslated region of the short kidney
ankyrin-3 transcripts that lack the repeat domain (Fig. 1),
Figure 2. Western blot analysis.
(A) Mouse kidney membranes
(50  mg) stained with a 1:500 dilu-
tion of the Ank3-R1 antibody.
(B) Mouse kidney membranes
stained with ANK3-R1 plus a
200-fold molar excess of GST.
(C) Mouse kidney membranes
stained with ANK3-R1 plus a
200-fold molar excess of the GST–
ankyrin-3 regulatory domain fu-
sion peptide used to generate
Ank3-R1. Note that there are
five major isoforms of ankyrin-3
expressed in the kidney, all of
which are detected by and spe-
cific to the Ank3-R1 antibody.
(D) Mouse bone marrow mac-
rophage extract (50 mg) stained
with Ank3-R1. (E) Mouse bone
marrow macrophage extract
stained with ANK3-R1 plus a 200-
fold molar excess of the Ank3-
R1 epitope. Note that only the
100- and 120-kD isoforms are
expressed in bone marrow mac-
rophages. Figure 3. RT-PCR analysis of bone marrow macrophage mRNA.
(A) Regulatory domain RT-PCR using REGF1 and REGR1
primers (See Materials and Methods and Fig. 1). Note two bands
(arrows) of z1,025 and 1,600 bp. These were subcloned (lanes H
and G, respectively) and sequenced. (C) Spectrin-binding domain
RT-PCR using SPINTF1 and SPR1 primers. Note one band of
z1,800 bp (arrow), which was subcloned (lane F) and sequenced.
Other bands shown in lane C were nonspecific products. (Lanes
B, D, and E) DNA size standards.Hoock et al. Ank3 Associates with Macrophage Lysosomes 1063
fails to yield any PCR product from macrophage cDNA. This
experiment suggests that the 59 end of the macrophage
cDNA is distinctive from the kidney clones. Analysis of
this region of macrophage ankyrin-3 via 59–rapid amplifi-
cation of cDNA ends (RACE) PCR confirms the presence
of upstream coding sequence (Fig. 4 B). Four separate
RACE reactions were performed using two different RNA
samples and two sets of primers (see Materials and Meth-
ods). Products generated from these experiments (Fig. 4 A)
end at base 2,280 (60) located at the 39 end of the 22nd
repeat. These data suggest the start site for macrophage
ankyrin-3 is 29 amino acids upstream of the spectrin-bind-
ing domain (Fig. 4 B). There are three other possible start
sites downstream to the first methionine encoded by the
sequence revealed in our 59-RACE experiment. All of
these methionine residues are in adequate Kozak contexts
(for review see 39) for efficient translation initialization.
We have assigned methionine806 (60) as the start site be-
cause it is the first in-frame methionine encoded in our 59-
RACE product. The cDNA sequence of full-length mac-
rophage ankyrin-3 has been deposited in (GenBank No.
U89275). The calculated molecular mass of this protein is
128,323 daltons, which is close to its estimated size of 120
kD based on mobility in SDS polyacrylamide gels. This
NH2 sequence corresponds to the extreme COOH-termi-
nal end of the membrane (“repeat”) domain (60), begin-
ning at the end of the last repeat. The 100-kD isoform cor-
responds to the full-length protein minus the acidic
regulatory domain insert (GenBank No. U89274; calcu-
lated molecular mass 106,827 daltons).
Ankyrin-3 Associates with Intracellular Vesicles in
the Macrophage
Immunofluorescence microscopy using the Ank3-R1 anti-
body, which recognizes both isoforms of ankyrin-3 ex-
pressed in macrophages, reveals that ankyrin-3 surrounds
intracellular vesicles throughout the macrophage cytoplasm
(Fig. 5, A and B) and is not associated with the plasma
membrane. This surprising result was confirmed with a
second antibody, 59Ank3, which also recognizes both iso-
forms of macrophage ankyrin-3 (data not shown). 59Ank3
was raised against a synthetic peptide representing the six
unique NH2-terminal residues of the small (105 and 120
kD) isoforms of kidney ankyrin-3, plus the first nine resi-
dues of the spectrin-binding domain (60) (Fig. 1). In con-
trast, an antibody directed against an alternatively spliced
exon of ankyrin-3 that is only present in the full-length
ankyrin-3 isoforms (Ank3-B; Fig. 1) (60) does not stain
macrophage membranes at all (data not shown). This ob-
servation supports the RT-PCR and immunoblotting ex-
periments, identifying vesicular ankyrin-3 as truncated iso-
forms.
Macrophage Ankyrin-3 cDNA Expression in COS Cells
The vesicular location of ankyrin-3 was further substanti-
ated by transient overexpression of HA-tagged ankyrin-3
in COS cells. HA was fused to the COOH terminus of
mouse macrophage ankyrin-3 and ligated into the pcDNA3
mammalian expression vector. The fusion protein was vi-
sualized using the 12CA5 mAb, which is directed against
the HA epitope. This experiment shows that macrophage
ankyrin-3 localizes to intracellular vesicle membranes and
not plasma membranes (Fig. 6). The vesicular location of
macrophage ankyrin-3 (Fig. 7 B) differs dramatically from
ankyrin-1, which is found in its characteristic position on
the plasma membrane (Fig. 7 A). The presence of ankyrin-
1 in macrophages was confirmed by immunoblotting (data
not shown).
Ankyrin-3–positive Vesicles Are Lysosomes
Because the dense appearance of the ankyrin-3–positive
vesicles suggested they might be lysosomes (56, 69), we
first tested their accessibility to endocytic tracers by incu-
bating macrophages with soluble fluorescein-conjugated
dextran (average Mr 5 10,000 daltons). After a brief 15-
min labeling pulse, we washed the cells and incubated
them for various chase times up to 24 h. We then fixed the
macrophages, localized ankyrin-3 with the Ank3-R1 anti-
body, and visualized it with rhodamine-conjugated anti-
IgG. None of the ankyrin-3–positive vesicles were filled
with fluorescent dextran at very early time points (Fig. 8,
A and B, arrowheads), and only a small fraction of the ves-
icles contained both fluorophores after a 6-h chase (Fig. 8,
C and D, arrows). In contrast, after 24 h, all the fluores-
cent dextran was located in ankyrin-3–positive vesicles
(Fig. 8, E and F, arrows). This indicates the vesicles are in
the endocytic pathway (5, 23, 24, 30, 38, 57, 72, 73). How-
ever, endocytic tracers can be chased out of endosomes
and into lysosomes within a few hours (25, 68, 71), while it
takes 24 h for dextran-containing endosomes to reach the
ankyrin-3–positive compartment. This suggests ankyrin-3–
positive vesicles are lysosomes instead of endosomes.
To examine this further, we stained macrophages for
rab9, a marker of late endosomes (47). Rab9 associates
with large, phase-light vesicles that were completely differ-
ent in appearance from ankyrin-3–positive or dextran-posi-
tive vesicles (data not shown). We also stained macrophages
with acridine orange, a marker for acidic compartments
Figure 4. RACE analysis of
the 59 end of macrophage
ankyrin-3. (A) 378-bp 59
RACE product using
A3MEMR3 for the reverse
transcription, and A3MEMR1
and A3MEMR2 for primary
and nested PCR reactions,
respectively. (B) Schematic
diagram of sequence en-
coded by the 59 end of mac-
rophage ankyrin-3.The Journal of Cell Biology, Volume 136, 1997 1064Hoock et al. Ank3 Associates with Macrophage Lysosomes 1065
(53). All phase-dense vesicles were acidic (data not shown),
which supports the argument that phase-dense, ankyrin-3–
positive vesicles are lysosomes.
Lastly, we stained macrophages with antibodies to
LAMP-1, a well-characterized lysosomal membrane glyco-
protein that has been used frequently as a marker for lyso-
somal compartments (9, 10, 20). After the 24 h chase, a
time point at which all ankyrin-3–positive vesicles are
filled with dextran, saponin-permeabilized cells reveal that
LAMP-1–positive vesicles are also filled with fluorescent
dextran (data not shown). Additionally, by simultaneously
colocalizing LAMP-1 and ankyrin-3 in macrophages that
were not exposed to dextran, we show that both of these
proteins associate with the same intracellular vesicles (Fig.
9, A and B, arrows). The LAMP-1 staining shown here is
not optimal in its intensity because we had to use higher
concentrations of saponin than those normally used for
LAMP-1 immunolocalization use to allow ankyrin-3 anti-
bodies to localize simultaneously (see Materials and Meth-
ods for more details). Also, under more optimal condi-
tions, LAMP-1 stains many phase-light lysosomes in the
perinuclear region of the cytoplasm.
Together these experiments demonstrate that ankyrin-3
is expressed in bone marrow–derived macrophages as two
isoforms that lack the NH2-terminal repeats and, within
these cells, resides on the intracellular membranes of
acidic, phase-dense, LAMP-1–positive lysosomes. The
presence of an ankyrin, which is normally associated with
Figure 5. Localization of ankyrin-3 in mouse bone marrow macrophages. (A and C) Phase-contrast photomicrographs. (B) Macrophage
stained with Ank3-R1 antibody (inset, high power view). (D) Preimmune serum. Note the intense staining surrounding phase-dense ves-
icles throughout the macrophage cytoplasm (A and B, arrowheads). Bar, 10 mm.
Figure 6. Localization of epitope-tagged macrophage ankyrin-3
expressed in COS cells. (A) Phase-contrast photomicrographs.
(B) COS cell stained with 12CA5 mAb against the HA epitope
that has been fused to macrophage ankyrin-3. Note the staining
pattern surrounding vesicles shown in phase contrast (arrows).
Bar, 10 mm.
Figure 7. Comparison of ankyrin-3 and ankyrin-1 (erythrocyte
ankyrin) localization in mouse bone marrow macrophages. (A)
Ankyrin-1 antibody. (B) Ank3-R1 antibody. Note that the
ankyrin-1 antiserum does not localize to intracellular membranes
and stains most of the surface plasma membrane, while the
ankyrin-3 antiserum only labels intracellular vesicles. Bar, 10 mm.The Journal of Cell Biology, Volume 136, 1997 1066
Figure 8. Simultaneous localization of ankyrin-3 and endocytically incorporated, FITC-labeled dextran. (A, C, and E) Ank3-R1 anti-
body. (B, D, and F) FITC-dextran. Cells were pulsed for 15 min with 1 mg/ml FITC-dextran, and then washed thoroughly and chased in
BMM media for 0 h (A and B), 6 h (C and D), and 24 h (E and F). Arrows and arrowheads indicate ankyrin-3–positive vesicles that do
or do not colocalize with FITC-dextran, respectively. Note that at 6 h a small subset of ankyrin-3–positive vesicles contain FITC-dex-
tran, but complete coincidence between ankyrin-3 and vesicular FITC-dextran does not occur until the 24-h chase period. Bar, 10 mm.Hoock et al. Ank3 Associates with Macrophage Lysosomes 1067
the plasma membrane and membrane skeleton, on the sur-
face of lysosomes raises the possibility that structures like
the membrane skeleton may also form on intracellular
membranes and influence their function.
Discussion
Ankyrin-3 Expression
Ankyrins have been localized to polarized plasma mem-
brane surfaces in a wide range of tissue types, including
cardiac and skeletal muscle, intestine, retinal, renal, gas-
tric, and airway epithelium, MDCK cells, initial segments
and the node of Ranvier in axons, dendrites, and the Tor-
pedo electrocyte (4, 19, 22, 26, 29, 31, 34–36, 44, 54, 60, 67).
In addition to diverse tissue expression, ankyrin-3 is char-
acterized by its unique isoforms, some of which are miss-
ing the 89-kD repeat domain (60) responsible for interac-
tions with integral membrane ion channels or adhesive
proteins (7, 12, 44, 50–52, 55). Since the isolated 62-kD
spectrin-binding domain of ankyrin-1 retains its stability
and capacity to bind spectrin (2, 62, 74), it is easy to believe
that the 120- and 105-kD isoforms of ankyrin-3, which con-
tain the spectrin-binding and regulatory domains, would be
stable and functional as well. It follows that if the domain
responsible for binding to plasma membrane–associated
proteins is missing, these spliced isoforms might localize to
membranes other than the plasma membrane.
Ankyrin-3 is expressed in epithelial cells as multiple iso-
forms ranging in size from 215 to 100 kD. The major differ-
ence between these isoforms is the presence or absence of
the NH2-terminal repeat domain. In cells that only express
the smaller two isoforms of ankyrin-3 that lack the repeat
domain, ankyrin-3 appears to be concentrated in the cyto-
plasm, not the plasma membrane (60). One of these cells is
the macrophage and, as shown here, macrophage ankyrin-
3 localizes exclusively to the intracellular membranes of
lysosomal vesicles. We are confident this is ankyrin-3, and
not another ankyrin, since antibodies raised to two differ-
ent regions of ankyrin-3 localize to the same membrane
surface and antibodies to ankyrin-1 show a different (and
more typical) plasma membrane staining pattern.
It is interesting that the 59 end of macrophage ankyrin-3
differs from the NH2-terminal truncated kidney 105- and
120-kD isoforms. Our 59-RACE analysis reveals that mac-
rophage ankyrin-3 encodes a short 29–amino acid se-
quence at its NH2-terminal end that corresponds to the fi-
nal 29 amino acids of the repeat domain. These amino
acids do not encode a repeat and are not conserved be-
tween ankyrins, suggesting a gene-specific function, but
could contain the lysosomal targeting sequence. This hypoth-
esis is supported by the vesicular localization of epitope-
tagged ankyrin-3 transiently expressed in COS cells. This
experiment demonstrates that macrophage ankyrin-3 con-
tains sequence information that can localize it to an intra-
cellular surface in cells other than macrophages. Since all
of the sequence of macrophage ankyrin-3 is contained
within the full-length (z210 kD) ankyrin-3, which is found
on plasma membranes in various tissues (37, 60), the intra-
cellular targeting sequence(s) must be blocked or inacti-
vated in the larger protein.
Ankyrin-3-positive Lysosomes
It is well established that soluble tracer molecules tagged
with fluorescent markers are useful in following the fluid
phase through the endocytic pathway over time (23–25, 30,
38, 57, 68, 71–73). Since we can chase one of these en-
docytic tracers, fluorescent dextran, into ankyrin-3–posi-
tive vesicles, the vesicles must be part of the endocytic
pathway.
The 24-h chase time required to obtain complete colo-
calization of endocytically incorporated dextrans and
ankyrin-3 (Fig. 8, E and F) suggests the ankyrin-3–positive
vesicles are lysosomes (25, 68, 71). This was confirmed by
the fact that dextran-containing vesicles are also positive
Figure 9. Colocalization of LAMP-1 and ankyrin-3 in mouse
macrophages. (A) Ankyrin-3. (B) LAMP-1. In this representative
cell, note the almost identical staining pattern in this region of the
cell (A and B, arrows). Bar, 10 mm.The Journal of Cell Biology, Volume 136, 1997 1068
for LAMP-1 at the 24-h chase time and by the fact that
LAMP-1 and ankyrin-3 colocalize when the staining con-
ditions for each antigen are carefully adjusted so that both
can be stained at the same time.
The colocalization experiment is difficult because im-
munofluorescence of ankyrin-3 and LAMP-1 staining var-
ies depending on the lysis conditions used. The number of
LAMP-1– and/or dextran-positive vesicles in macrophages
decreases when high concentrations of saponin or Triton
X-100 are used for lysis (conditions that are optimal for
ankyrin-3 labeling), while ankyrin-3 cannot be detected
when low concentrations of saponin are used (optimal con-
ditions for LAMP-1). In addition, the dark, phase-dense
appearance of macrophage lysosomes correlates with the
vesicles’ ability to retain ankyrin-3 staining (Hoock, T.C.,
unpublished observations). It is important to note that
macrophages grown from bone marrow do not all contain
phase-dense vesicles. Anti–ankyrin-3 antibodies do not re-
act with cells that lack phase-dense vesicles. We have tried
many cytokines and stimulatory agents to induce their ex-
pression: tumor necrosis factor a, interleukin (IL)-1a, IL-4,
IL-10, IL-13, gamma interferon, and PMA. While many of
these had effects on cell morphology and growth rate,
none increased the number of ankyrin-3–positive, phase-
dense lysosomes.
We do not understand what controls the expression of
phase-dense vesicles in macrophages; however, they seem
to increase in number when cells become fully differenti-
ated and stop dividing, and when replated from primary
culture before cells reach confluent density (Hoock, T.C.,
unpublished observations). Furthermore, resident mac-
rophages isolated from the peritoneal cavity of mice also
show that ankyrin-3 associated with intracellular vesicles,
while an immortal macrophage cell line, J774, does not
stain for intracellular ankyrin-3 (data not shown). Prelimi-
nary data from experiments in which we fed increasing
amounts of unlabeled dextran to macrophages show a cor-
relation with increasing numbers of ankyrin-3–positive
vesicles (Hoock, T.C., unpublished data). This experiment
suggests that cells respond to an increase in endocytic ma-
terial by increasing the number of endocytic vesicles to
house the material. It remains to be seen whether an in-
crease in the expression of ankyrin-3 is observed before or
after an increase in endocytic material being ingested.
Intracellular Membrane Skeletons
Using the red cell plasma membrane skeleton as a model,
one might expect to find other skeletal proteins on vesicle
membranes. Preliminary experiments suggest the vesicles
contain b-spectrin (two of 10 antisera tested) (data not
shown). One of these antibodies, raised against b-spectrin
from canine red cells, also associates with the intracellular
membranes of the Golgi apparatus in MDCK cells (1).
Macrophage lysosomes were not stained by antisera raised
against a-spectrin (0 of nine antisera), fodrin (0 of three
antisera), protein 4.1 (0 of two antisera), adducin (0 of one
antiserum), or b-actin (0 of one antiserum). Numerous at-
tempts to identify interactions between ankyrin-3 and
spectrin by immunoprecipitation combined with Western
blotting were unsuccessful, in part because we were unable
to completely inhibit macrophage protease activities with
multiple combinations of protease inhibitors, including di-
isopropylfluorophosphate.
Band 3 (32), b-spectrin (1), and, more recently, ankyrin-3
(18) have been localized to Golgi membranes in MDCK
cells. The isoform of ankyrin associated with Golgi in kid-
ney and muscle has recently been identified and is a previ-
ously unknown isoform of ankyrin-3 (AnkG119). It contains
the last 13 of the 24 repeats in the NH2-terminal domain,
the complete spectrin-binding domain, and a unique, trun-
cated (5 kD) regulatory domain. AnkG119 binds avidly to
b1 (erythrocyte/muscle) spectrins (Kd 5 4.2 nM) but not
to a-spectrin (18). Since the spectrin-binding domains of
AnkG119 and lysosomal ankyrin-3 are highly conserved, it
is likely that lysosomal ankyrin-3 also binds b-spectrin. In
fact, as noted in the previous paragraph, our preliminary
experiments show that mouse macrophage lysosomes stain
with some b-spectrin antisera, including an antiserum that
sees Golgi spectrin (1).
In macrophages, anti–ankyrin-3 antibodies did not stain
plasma membranes and were never found in a perinuclear
position, suggesting that macrophage ankyrin-3 isoforms,
which differ from those expressed in MDCK cells, do not
reside in the Golgi apparatus or the ER. Based on these
observations, we hypothesize that ankyrin-3 is translated
in the cytoplasm on demand and quickly diffuses or is
shuttled to lysosomal membranes.
Overall, the presence of these membrane skeleton pro-
teins, previously thought to only associate with the plasma
membrane, on intracellular organelles entices speculation
about their possible functions. If part of a vesicular mem-
brane skeleton, ankyrin could: (a) strengthen the mem-
brane of the vesicle and prevent “accidental” leakage of its
contents into the cytoplasm; (b) prevent spontaneous or
promiscuous fusion or exocytosis of vesicles; (c) influence
trafficking of endocytic/trafficking vesicles by interacting
with motor and/or motor docking proteins; (d) localize a
specific membrane channel to establish or maintain the in-
travesicular milieu; or perhaps (e) contribute to the regula-
tion of vesicle/organelle biogenesis. Continued work on
these questions will no doubt yield interesting roles for
this class of proteins in the biology of intracellular mem-
branes.
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